You might also like
ADMA Biologics, Inc. is a commercial biopharmaceutical company focused on the manufacturing, marketing, and development of specialty plasma-derived biologics. The company primarily targets immunodeficient patients at risk for infections and other individuals at risk for certain infectious diseases. ADMA sells FDA-approved immunoglobulin products, including BIVIGAM, ASCENIV, and Nabi-HB, as well as intermediate by-products from the immunoglobulin production process.
-
ADMA BioManufacturing - Manufactures and markets specialty plasma-derived biologics, including FDA-approved products like BIVIGAM and ASCENIV, which are intravenous immune globulin products for treating Primary Humoral Immunodeficiency.
-
Plasma Collection Centers - Operates ten FDA-approved plasma collection facilities throughout the United States, supplying plasma for ADMA's manufacturing processes.
-
Corporate - Provides administrative support and overhead for the company's operations.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Adam S. Grossman ExecutiveBoard | President and Chief Executive Officer (CEO) | Chair of the North America Board of Directors of the Plasma Protein Therapeutics Association | Adam S. Grossman has been the CEO of ADMA Biologics since October 2011. He also currently serves as Interim CFO since April 2024 and has been a director of the company since 2007. | View Report → |
Kaitlin Kestenberg Executive | Chief Operating Officer and Senior Vice President, Compliance | Kaitlin Kestenberg has been the Chief Operating Officer and Senior Vice President, Compliance at ADMA since April 1, 2024, and she has held multiple leadership roles at ADMA since 2011, progressing through various VP and directorial positions. | ||
Alison C. Finger Board | Board Director (Class I Director) | Independent director at KeifeRx LLC | Alison C. Finger joined the ADMA Board of Directors as a Class I director on September 28, 2023. She brings over 30 years of leadership experience in biotech and pharmaceuticals, having served in executive roles at bluebird bio and Bristol-Myers Squibb. | |
Dr. Jerrold Grossman Board | Vice Chairman of the Board | CEO of Technomed, Inc. ; President of GenesisBPS ; Member of Corporate Advisory Council of Lakeland Bancorp Inc. | Dr. Jerrold Grossman is a co-founder of ADMA Biologics and has been a director since 2007. He served as the part-time CEO from 2007 until October 2011 and is now the Vice Chairman of the Board. | |
Eduardo Rene Salas Board | Class I Director | Audit Committee Member at Intra-Cellular Therapies, Inc. | Eduardo Rene Salas joined ADMA as a Class I Director on December 30, 2024, and has an extensive background in financial leadership, having served in roles such as Senior Client Serving Audit Partner at Ernst & Young and CFO at Wellstat Therapeutics. | |
Lawrence Guiheen Board | Director | Lawrence Guiheen has over 35 years of experience in the healthcare industry and became a director at ADMA in July 2012. He currently serves as Chairman of the Governance and Nominations Committee and as a member of the Audit and Compensation Committees. | ||
Steven A. Elms Board | Chairman of the Board | Managing Partner at Aisling Capital; Board member of Elevation Oncology (Nasdaq: ELEV); Board member of Marker Therapeutics (Nasdaq: MRKR); Board member of Treeline Biosciences | Steven A. Elms has been with ADMA Biologics since 2007 as a director and currently serves as the Chairman of the Board while also participating in the Governance and Nominations Committee and, from November 19, 2024, the Audit Committee. | |
Young T. Kwon Board | Director | CEO of Alchemab Therapeutics | Young T. Kwon, PhD has served as a Director at ADMA since October 2021 and holds significant committee roles including Chairman of the Compensation Committee and Audit Committee responsibilities (appointed as Chairman of the Audit Committee on November 19, 2024 ). He has extensive industry experience, notably as the CEO of Alchemab Therapeutics and in senior roles at Momenta Pharmaceuticals and Biogen. | |
Brian Lenz | Consultant | Brian Lenz served as Executive Vice President, CFO & General Manager of ADMA BioCenters for 11 years, contributing to the company's public listing and expansion. Effective April 1, 2024, he transitioned to a consulting role at ADMA. |
- Based on your current guidance that excludes yield enhancement for 2025, can you detail how the additional 20% IG output will be allocated between ASCENIV and BIVIGAM, and what mix assumptions are driving your projections?
- Given your plans for increasing plasma collections, what specific operational challenges do you foresee in scaling both internal and third-party high-titer plasma procurement while maintaining margin expansion and production efficiencies?
- Can you provide a clearer roadmap and timeline for onboarding the remaining third-party supply contracts, and what safeguards are in place to ensure that quality and testing throughput are not compromised as you expand?
- With the growing queue of prospective ASCENIV patients, what risks do you anticipate if delays occur in transitioning patients from their current IG therapies, and how might extended wait times impact your revenue and market share?
- Regarding the enhanced yield production process, can you elaborate on the key regulatory milestones and potential hurdles you might face with the FDA review that could delay its implementation and affect your financial upside?
Recent press releases and 8-K filings for ADMA.
- Total Revenue reached $114.8 million in Q1 2025 with a 40% year-over-year increase and GAAP Net Income of $26.9 million, reflecting strong margin and EBITDA growth.
- The company received FDA approval for its yield enhancement process, expected to generate 20% more product from the same plasma volumes, supporting margin expansion.
- Guidance Update: FY 2025 revenue guidance was raised to over $500 million and FY 2026 to over $625 million, along with improved adjusted EBITDA forecasts.
- The Board authorized a $500 million share repurchase program, representing approximately 8% of current market capitalization to enhance shareholder value.
- ADMA Biologics announced U.S. FDA approval for an innovative production yield enhancement process expected to boost production yields by approximately 20% from the same starting plasma volume.
- The new process is anticipated to drive revenue acceleration and margin expansion, benefiting multiple plasma-derived products and supporting future growth in late 2025 and into 2026.
- FY 2024 Total Revenue: Reached $426.5 million, a 65% YoY increase driven by higher ASCENIV sales, with GAAP net income turning positive at $197.7 million .
- Adjusted EBITDA Improvement: Achieved $164.6 million with a 309% YoY increase, reflecting robust operational performance .
- Margin Expansion: Gross margin increased from 34.4% in 2023 to 51.5% in 2024, owing to a more favorable sales mix and cost efficiencies .
- Updated Guidance: FY 2025 revenues are now expected to exceed $490 million and FY 2026 $605 million, with corresponding improvements in adjusted EBITDA .
- Long-Term Growth Prospects: The company anticipates surpassing $1 billion in annual revenue before 2030, supported by long-term plasma supply contracts and pending yield enhancement regulatory approval .